IBDEI367 ; ; 04-FEB-2020
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,50623,2)
;;=^5001814
;;^UTILITY(U,$J,358.3,50624,0)
;;=C92.A0^^193^2497^12
;;^UTILITY(U,$J,358.3,50624,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,50624,1,3,0)
;;=3^Acute Myeloid Leukemia w/ Multilin Dysplasia,Not in Remission
;;^UTILITY(U,$J,358.3,50624,1,4,0)
;;=4^C92.A0
;;^UTILITY(U,$J,358.3,50624,2)
;;=^5001813
;;^UTILITY(U,$J,358.3,50625,0)
;;=C92.51^^193^2497^13
;;^UTILITY(U,$J,358.3,50625,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,50625,1,3,0)
;;=3^Acute Myelomonocytic Leukemia,In Remission
;;^UTILITY(U,$J,358.3,50625,1,4,0)
;;=4^C92.51
;;^UTILITY(U,$J,358.3,50625,2)
;;=^5001805
;;^UTILITY(U,$J,358.3,50626,0)
;;=C92.50^^193^2497^14
;;^UTILITY(U,$J,358.3,50626,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,50626,1,3,0)
;;=3^Acute Myelomonocytic Leukemia,Not in Remission
;;^UTILITY(U,$J,358.3,50626,1,4,0)
;;=4^C92.50
;;^UTILITY(U,$J,358.3,50626,2)
;;=^5001804
;;^UTILITY(U,$J,358.3,50627,0)
;;=C94.40^^193^2497^17
;;^UTILITY(U,$J,358.3,50627,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,50627,1,3,0)
;;=3^Acute Panmyelosis w/ Myelofibrosis,Not in Remission
;;^UTILITY(U,$J,358.3,50627,1,4,0)
;;=4^C94.40
;;^UTILITY(U,$J,358.3,50627,2)
;;=^5001843
;;^UTILITY(U,$J,358.3,50628,0)
;;=C94.42^^193^2497^15
;;^UTILITY(U,$J,358.3,50628,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,50628,1,3,0)
;;=3^Acute Panmyelosis w/ Myelofibrosis,In Relapse
;;^UTILITY(U,$J,358.3,50628,1,4,0)
;;=4^C94.42
;;^UTILITY(U,$J,358.3,50628,2)
;;=^5001845
;;^UTILITY(U,$J,358.3,50629,0)
;;=C94.41^^193^2497^16
;;^UTILITY(U,$J,358.3,50629,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,50629,1,3,0)
;;=3^Acute Panmyelosis w/ Myelofibrosis,In Remission
;;^UTILITY(U,$J,358.3,50629,1,4,0)
;;=4^C94.41
;;^UTILITY(U,$J,358.3,50629,2)
;;=^5001844
;;^UTILITY(U,$J,358.3,50630,0)
;;=D62.^^193^2497^18
;;^UTILITY(U,$J,358.3,50630,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,50630,1,3,0)
;;=3^Acute Posthemorrhagic Anemia
;;^UTILITY(U,$J,358.3,50630,1,4,0)
;;=4^D62.
;;^UTILITY(U,$J,358.3,50630,2)
;;=^267986
;;^UTILITY(U,$J,358.3,50631,0)
;;=C92.41^^193^2497^19
;;^UTILITY(U,$J,358.3,50631,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,50631,1,3,0)
;;=3^Acute Promyelocytic Leukemia,In Remission
;;^UTILITY(U,$J,358.3,50631,1,4,0)
;;=4^C92.41
;;^UTILITY(U,$J,358.3,50631,2)
;;=^5001802
;;^UTILITY(U,$J,358.3,50632,0)
;;=C92.40^^193^2497^20
;;^UTILITY(U,$J,358.3,50632,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,50632,1,3,0)
;;=3^Acute Promyelocytic Leukemia,Not in Remission
;;^UTILITY(U,$J,358.3,50632,1,4,0)
;;=4^C92.40
;;^UTILITY(U,$J,358.3,50632,2)
;;=^5001801
;;^UTILITY(U,$J,358.3,50633,0)
;;=D56.0^^193^2497^21
;;^UTILITY(U,$J,358.3,50633,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,50633,1,3,0)
;;=3^Alpha Thalassemia
;;^UTILITY(U,$J,358.3,50633,1,4,0)
;;=4^D56.0
;;^UTILITY(U,$J,358.3,50633,2)
;;=^340494
;;^UTILITY(U,$J,358.3,50634,0)
;;=D63.1^^193^2497^23
;;^UTILITY(U,$J,358.3,50634,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,50634,1,3,0)
;;=3^Anemia in Chronic Kidney Disease
;;^UTILITY(U,$J,358.3,50634,1,4,0)
;;=4^D63.1
;;^UTILITY(U,$J,358.3,50634,2)
;;=^332908
;;^UTILITY(U,$J,358.3,50635,0)
;;=D63.0^^193^2497^24
;;^UTILITY(U,$J,358.3,50635,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,50635,1,3,0)
;;=3^Anemia in Neoplastic Disease
;;^UTILITY(U,$J,358.3,50635,1,4,0)
;;=4^D63.0
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI367 3786 printed Dec 13, 2024@02:42:35 Page 2
IBDEI367 ; ; 04-FEB-2020
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,50623,2)
+2 ;;=^5001814
+3 ;;^UTILITY(U,$J,358.3,50624,0)
+4 ;;=C92.A0^^193^2497^12
+5 ;;^UTILITY(U,$J,358.3,50624,1,0)
+6 ;;=^358.31IA^4^2
+7 ;;^UTILITY(U,$J,358.3,50624,1,3,0)
+8 ;;=3^Acute Myeloid Leukemia w/ Multilin Dysplasia,Not in Remission
+9 ;;^UTILITY(U,$J,358.3,50624,1,4,0)
+10 ;;=4^C92.A0
+11 ;;^UTILITY(U,$J,358.3,50624,2)
+12 ;;=^5001813
+13 ;;^UTILITY(U,$J,358.3,50625,0)
+14 ;;=C92.51^^193^2497^13
+15 ;;^UTILITY(U,$J,358.3,50625,1,0)
+16 ;;=^358.31IA^4^2
+17 ;;^UTILITY(U,$J,358.3,50625,1,3,0)
+18 ;;=3^Acute Myelomonocytic Leukemia,In Remission
+19 ;;^UTILITY(U,$J,358.3,50625,1,4,0)
+20 ;;=4^C92.51
+21 ;;^UTILITY(U,$J,358.3,50625,2)
+22 ;;=^5001805
+23 ;;^UTILITY(U,$J,358.3,50626,0)
+24 ;;=C92.50^^193^2497^14
+25 ;;^UTILITY(U,$J,358.3,50626,1,0)
+26 ;;=^358.31IA^4^2
+27 ;;^UTILITY(U,$J,358.3,50626,1,3,0)
+28 ;;=3^Acute Myelomonocytic Leukemia,Not in Remission
+29 ;;^UTILITY(U,$J,358.3,50626,1,4,0)
+30 ;;=4^C92.50
+31 ;;^UTILITY(U,$J,358.3,50626,2)
+32 ;;=^5001804
+33 ;;^UTILITY(U,$J,358.3,50627,0)
+34 ;;=C94.40^^193^2497^17
+35 ;;^UTILITY(U,$J,358.3,50627,1,0)
+36 ;;=^358.31IA^4^2
+37 ;;^UTILITY(U,$J,358.3,50627,1,3,0)
+38 ;;=3^Acute Panmyelosis w/ Myelofibrosis,Not in Remission
+39 ;;^UTILITY(U,$J,358.3,50627,1,4,0)
+40 ;;=4^C94.40
+41 ;;^UTILITY(U,$J,358.3,50627,2)
+42 ;;=^5001843
+43 ;;^UTILITY(U,$J,358.3,50628,0)
+44 ;;=C94.42^^193^2497^15
+45 ;;^UTILITY(U,$J,358.3,50628,1,0)
+46 ;;=^358.31IA^4^2
+47 ;;^UTILITY(U,$J,358.3,50628,1,3,0)
+48 ;;=3^Acute Panmyelosis w/ Myelofibrosis,In Relapse
+49 ;;^UTILITY(U,$J,358.3,50628,1,4,0)
+50 ;;=4^C94.42
+51 ;;^UTILITY(U,$J,358.3,50628,2)
+52 ;;=^5001845
+53 ;;^UTILITY(U,$J,358.3,50629,0)
+54 ;;=C94.41^^193^2497^16
+55 ;;^UTILITY(U,$J,358.3,50629,1,0)
+56 ;;=^358.31IA^4^2
+57 ;;^UTILITY(U,$J,358.3,50629,1,3,0)
+58 ;;=3^Acute Panmyelosis w/ Myelofibrosis,In Remission
+59 ;;^UTILITY(U,$J,358.3,50629,1,4,0)
+60 ;;=4^C94.41
+61 ;;^UTILITY(U,$J,358.3,50629,2)
+62 ;;=^5001844
+63 ;;^UTILITY(U,$J,358.3,50630,0)
+64 ;;=D62.^^193^2497^18
+65 ;;^UTILITY(U,$J,358.3,50630,1,0)
+66 ;;=^358.31IA^4^2
+67 ;;^UTILITY(U,$J,358.3,50630,1,3,0)
+68 ;;=3^Acute Posthemorrhagic Anemia
+69 ;;^UTILITY(U,$J,358.3,50630,1,4,0)
+70 ;;=4^D62.
+71 ;;^UTILITY(U,$J,358.3,50630,2)
+72 ;;=^267986
+73 ;;^UTILITY(U,$J,358.3,50631,0)
+74 ;;=C92.41^^193^2497^19
+75 ;;^UTILITY(U,$J,358.3,50631,1,0)
+76 ;;=^358.31IA^4^2
+77 ;;^UTILITY(U,$J,358.3,50631,1,3,0)
+78 ;;=3^Acute Promyelocytic Leukemia,In Remission
+79 ;;^UTILITY(U,$J,358.3,50631,1,4,0)
+80 ;;=4^C92.41
+81 ;;^UTILITY(U,$J,358.3,50631,2)
+82 ;;=^5001802
+83 ;;^UTILITY(U,$J,358.3,50632,0)
+84 ;;=C92.40^^193^2497^20
+85 ;;^UTILITY(U,$J,358.3,50632,1,0)
+86 ;;=^358.31IA^4^2
+87 ;;^UTILITY(U,$J,358.3,50632,1,3,0)
+88 ;;=3^Acute Promyelocytic Leukemia,Not in Remission
+89 ;;^UTILITY(U,$J,358.3,50632,1,4,0)
+90 ;;=4^C92.40
+91 ;;^UTILITY(U,$J,358.3,50632,2)
+92 ;;=^5001801
+93 ;;^UTILITY(U,$J,358.3,50633,0)
+94 ;;=D56.0^^193^2497^21
+95 ;;^UTILITY(U,$J,358.3,50633,1,0)
+96 ;;=^358.31IA^4^2
+97 ;;^UTILITY(U,$J,358.3,50633,1,3,0)
+98 ;;=3^Alpha Thalassemia
+99 ;;^UTILITY(U,$J,358.3,50633,1,4,0)
+100 ;;=4^D56.0
+101 ;;^UTILITY(U,$J,358.3,50633,2)
+102 ;;=^340494
+103 ;;^UTILITY(U,$J,358.3,50634,0)
+104 ;;=D63.1^^193^2497^23
+105 ;;^UTILITY(U,$J,358.3,50634,1,0)
+106 ;;=^358.31IA^4^2
+107 ;;^UTILITY(U,$J,358.3,50634,1,3,0)
+108 ;;=3^Anemia in Chronic Kidney Disease
+109 ;;^UTILITY(U,$J,358.3,50634,1,4,0)
+110 ;;=4^D63.1
+111 ;;^UTILITY(U,$J,358.3,50634,2)
+112 ;;=^332908
+113 ;;^UTILITY(U,$J,358.3,50635,0)
+114 ;;=D63.0^^193^2497^24
+115 ;;^UTILITY(U,$J,358.3,50635,1,0)
+116 ;;=^358.31IA^4^2
+117 ;;^UTILITY(U,$J,358.3,50635,1,3,0)
+118 ;;=3^Anemia in Neoplastic Disease
+119 ;;^UTILITY(U,$J,358.3,50635,1,4,0)
+120 ;;=4^D63.0
